Andrew Charles Barker

Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom.

Oxford Brain Diagnostics Ltd. engages in the development of cortical disarray measurement platform for diagnosis of Alzheimer’s disease. It also identifies other brain conditions. The company was founded by Steven Chance and Mark Jenkinson and is headquartered in Oxford, the United Kingdom.

Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom.